Department of Pediatrics, University of California San Diego, La Jolla, CA, United States.
Institute of Genomic Medicine, University of California San Diego, La Jolla, CA, United States.
Front Endocrinol (Lausanne). 2024 Feb 20;15:1258982. doi: 10.3389/fendo.2024.1258982. eCollection 2024.
Genome-wide association studies have identified several hundred loci associated with type 2 diabetes mellitus (T2DM). Additionally, pathogenic variants in several genes are known to cause monogenic diabetes that overlaps clinically with T2DM. Whole-exome sequencing of related individuals with T2DM is a powerful approach to identify novel high-penetrance disease variants in coding regions of the genome. We performed whole-exome sequencing on four related individuals with T2DM - including one individual diagnosed at the age of 33 years. The individuals were negative for mutations in monogenic diabetes genes, had a strong family history of T2DM, and presented with several characteristics of metabolic syndrome. A missense variant (p.N2291D) in the type 2 ryanodine receptor ( gene was one of eight rare coding variants shared by all individuals. The variant was absent in large population databases and affects a highly conserved amino acid located in a mutational hotspot for pathogenic variants in Catecholaminergic polymorphic ventricular tachycardia (CPVT). Electrocardiogram data did not reveal any cardiac abnormalities except a lower-than-normal resting heart rate (< 60 bpm) in two individuals - a phenotype observed in CPVT individuals with mutations. RyR2-mediated Ca release contributes to glucose-mediated insulin secretion and pathogenic mutations cause glucose intolerance in humans and mice. Analysis of glucose tolerance testing data revealed that missense mutations in a CPVT mutation hotspot region - overlapping the p.N2291D variant - are associated with complete penetrance for glucose intolerance. In conclusion, we have identified an atypical missense variant in the gene that co-segregates with diabetes in the absence of overt CPVT.
全基因组关联研究已经确定了数百个与 2 型糖尿病(T2DM)相关的位点。此外,已知几个基因中的致病变异会导致与 T2DM 临床重叠的单基因糖尿病。对 T2DM 相关个体进行外显子组测序是一种识别基因组编码区域中新的高外显率疾病变异的有效方法。我们对 4 名 T2DM 相关个体进行了外显子组测序,其中包括一名 33 岁确诊的个体。这些个体未携带单基因糖尿病基因的突变,有强烈的 T2DM 家族史,并有代谢综合征的几个特征。2 型兰尼碱受体(基因中的错义变异(p.N2291D)是所有个体共有的 8 个罕见编码变异之一。该变异在大型人群数据库中不存在,并且影响位于儿茶酚胺多形性室性心动过速(CPVT)致病变异热点的高度保守氨基酸。除了两名个体的静息心率低于正常水平(<60 次/分)外,心电图数据未显示任何心脏异常 - 这是 CPVT 个体中观察到的表型,这些个体携带有突变。RyR2 介导的 Ca 释放有助于葡萄糖介导的胰岛素分泌,致病性突变导致人类和小鼠的葡萄糖耐量受损。葡萄糖耐量测试数据的分析表明,CPVT 突变热点区域(重叠 p.N2291D 变异)中的错义突变与葡萄糖耐量完全外显相关。总之,我们已经在基因中鉴定出一个非典型的错义变异,该变异在没有明显 CPVT 的情况下与糖尿病共分离。